Skip to main content
Top
Published in: Critical Care 1/2011

Open Access 01-02-2011 | Research

Plasma soluble vascular endothelial growth factor receptor-1 levels predict outcomes of pneumonia-related septic shock patients: a prospective observational study

Authors: Kuang-Yao Yang, Kuan-Ting Liu, Yu-Chun Chen, Chun-Sheng Chen, Yu-Chin Lee, Reury-Perng Perng, Jia-Yih Feng

Published in: Critical Care | Issue 1/2011

Login to get access

Abstract

Introduction

Despite recent advances in the management of septic shock, mortality rates are still unacceptably high. Early identification of the high-mortality risk group for early intervention remains an issue under exploration. Vascular endothelial growth factor (VEGF), soluble vascular endothelial growth factor receptor-1 (sVEGFR1) and urokinase plasminogen activator (uPA) have diverse effects in the pathogenesis of sepsis, which involve pro-inflammation, anti-inflammation, endothelial cell repair, and vascular permeability change. Their roles in predicting mortality and organ dysfunction remain to be clarified.

Methods

Pneumonia-related septic shock patients from medical intensive care units were enrolled for this prospective observational study. We also included 20 patients with pneumonia without organ dysfunction for comparison. Plasma levels of VEGF and sVEGFR1 and uPA activity within 24 hours of shock onset were measured. We compared plasma levels of these biomarkers with APACHE II scores between subgroups of patients, and evaluated their predictive value for 28-day mortality and organ dysfunction.

Results

A total of 101 patients, including 81 with pneumonia-related septic shock and 20 with pneumonia without organ dysfunction, were enrolled. Non-survivors of septic shock had significantly higher plasma sVEGFR1 levels (659.3 ± 1022.8 vs. 221.1 ± 268.9 pg/mL, respectively, P < 0.001) and uPA activity (47.2 ± 40.6 vs. 27.6 ± 17.2 units, respectively, P = 0.001) when compared with those of the survivors. Kaplan-Meier survival analysis demonstrated significantly higher mortality in patients with higher levels of sVEGFR1 (P < 0.001) and uPA activity (P = 0.031). In Cox regression analysis, plasma sVEGFR1 level was independently associated with, and best predicted, the 28-day mortality of septic shock (HR: 1.55, 95% CI: 1.05-2.30). Plasma sVEGFR1 level and uPA activity had good correlation with renal dysfunction, metabolic acidosis, and hematologic dysfunction; their levels significantly increased when the number of organ dysfunctions increased. In multivariate analysis, plasma sVEGFR1 level (HR: 2.82, 95% CI: 1.17-6.81) and uPA activity (HR: 2.75, 95% CI: 1.06-7.13) were independent predictors of the presence of concomitant multi-organ dysfunction. The predictive value of VEGF for mortality and organ dysfunction was limited in pneumonia-related septic shock patients.

Conclusions

High plasma sVEGFR1 level in the early stage of pneumonia-related septic shock independently predicted 28-day mortality and multi-organ dysfunction.
Appendix
Available only for authorised users
Literature
1.
go back to reference Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, Schein RM, Sibbald WJ: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 1992, 101: 1644-1655. 10.1378/chest.101.6.1644PubMedCrossRef Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, Schein RM, Sibbald WJ: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 1992, 101: 1644-1655. 10.1378/chest.101.6.1644PubMedCrossRef
2.
go back to reference Hotchkiss RS, Karl IE: The pathophysiology and treatment of sepsis. N Engl J Med 2003, 348: 138-150. 10.1056/NEJMra021333PubMedCrossRef Hotchkiss RS, Karl IE: The pathophysiology and treatment of sepsis. N Engl J Med 2003, 348: 138-150. 10.1056/NEJMra021333PubMedCrossRef
3.
go back to reference Russell JA, Singer J, Bernard GR, Wheeler A, Fulkerson W, Hudson L, Schein R, Summer W, Wright P, Walley KR: Changing pattern of organ dysfunction in early human sepsis is related to mortality. Crit Care Med 2000, 28: 3405-3411. 10.1097/00003246-200010000-00005PubMedCrossRef Russell JA, Singer J, Bernard GR, Wheeler A, Fulkerson W, Hudson L, Schein R, Summer W, Wright P, Walley KR: Changing pattern of organ dysfunction in early human sepsis is related to mortality. Crit Care Med 2000, 28: 3405-3411. 10.1097/00003246-200010000-00005PubMedCrossRef
4.
go back to reference Annane D, Aegerter P, Jars-Guincestre MC, Guidet B, CUB-Réa Network: Current epidemiology of septic shock: the CUB-Réa Network. Am J Respir Crit Care Med 2003, 168: 165-172. 10.1164/rccm.2201087PubMedCrossRef Annane D, Aegerter P, Jars-Guincestre MC, Guidet B, CUB-Réa Network: Current epidemiology of septic shock: the CUB-Réa Network. Am J Respir Crit Care Med 2003, 168: 165-172. 10.1164/rccm.2201087PubMedCrossRef
5.
go back to reference Christaki E, Opal SM: Is the mortality rate for septic shock really decreasing? Curr Opin Crit Care 2008, 14: 580-586. 10.1097/MCC.0b013e32830f1e25PubMedCrossRef Christaki E, Opal SM: Is the mortality rate for septic shock really decreasing? Curr Opin Crit Care 2008, 14: 580-586. 10.1097/MCC.0b013e32830f1e25PubMedCrossRef
6.
go back to reference Bastarache JA, Ware LB, Bernard GR: The role of the coagulation cascade in the continuum of sepsis and acute lung injury and acute respiratory distress syndrome. Semin Respir Crit Care Med 2006, 27: 365-376. 10.1055/s-2006-948290PubMedCrossRef Bastarache JA, Ware LB, Bernard GR: The role of the coagulation cascade in the continuum of sepsis and acute lung injury and acute respiratory distress syndrome. Semin Respir Crit Care Med 2006, 27: 365-376. 10.1055/s-2006-948290PubMedCrossRef
7.
go back to reference Berse B, Brown LF, Van de Water L, Dvorak HF, Senger DR: Vascular permeability factor (vascular endothelial growth factor) gene is expressed differentially in normal tissues, macrophages, and tumors. Mol Biol Cell 1992, 3: 211-220.PubMedPubMedCentralCrossRef Berse B, Brown LF, Van de Water L, Dvorak HF, Senger DR: Vascular permeability factor (vascular endothelial growth factor) gene is expressed differentially in normal tissues, macrophages, and tumors. Mol Biol Cell 1992, 3: 211-220.PubMedPubMedCentralCrossRef
8.
go back to reference Ferrara N: Molecular and biological properties of vascular endothelial growth factor. J Mol Med 1999, 77: 527-543. 10.1007/s001099900019PubMedCrossRef Ferrara N: Molecular and biological properties of vascular endothelial growth factor. J Mol Med 1999, 77: 527-543. 10.1007/s001099900019PubMedCrossRef
9.
go back to reference Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, Dvorak HF: Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 1983, 219: 983-985. 10.1126/science.6823562PubMedCrossRef Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, Dvorak HF: Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 1983, 219: 983-985. 10.1126/science.6823562PubMedCrossRef
10.
go back to reference Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N: Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989, 246: 1306-1309. 10.1126/science.2479986PubMedCrossRef Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N: Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989, 246: 1306-1309. 10.1126/science.2479986PubMedCrossRef
11.
go back to reference de Vries C, Escobedo JA, Ueno H, Houck K, Ferrara N, Williams LT: The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science 1992, 255: 989-991. 10.1126/science.1312256PubMedCrossRef de Vries C, Escobedo JA, Ueno H, Houck K, Ferrara N, Williams LT: The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science 1992, 255: 989-991. 10.1126/science.1312256PubMedCrossRef
12.
go back to reference Terman BI, Dougher-Vermazen M, Carrion ME, Dimitrov D, Armellino DC, Gospodarowicz D, Böhlen P: Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor. Biochem Biophys Res Commun 1992, 187: 1579-1586. 10.1016/0006-291X(92)90483-2PubMedCrossRef Terman BI, Dougher-Vermazen M, Carrion ME, Dimitrov D, Armellino DC, Gospodarowicz D, Böhlen P: Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor. Biochem Biophys Res Commun 1992, 187: 1579-1586. 10.1016/0006-291X(92)90483-2PubMedCrossRef
13.
go back to reference Kendall RL, Wang G, Thomas KA: Identification of a natural soluble form of the vascular endothelial growth factor receptor, FLT-1, and its heterodimerization with KDR. Biochem Biophys Res Commun 1996, 226: 324-328. 10.1006/bbrc.1996.1355PubMedCrossRef Kendall RL, Wang G, Thomas KA: Identification of a natural soluble form of the vascular endothelial growth factor receptor, FLT-1, and its heterodimerization with KDR. Biochem Biophys Res Commun 1996, 226: 324-328. 10.1006/bbrc.1996.1355PubMedCrossRef
14.
go back to reference Pickkers P, Sprong T, Eijk L, Hoeven H, Smits P, Deuren M: Vascular endothelial growth factor is increased during the first 48 hours of human septic shock and correlates with vascular permeability. Shock 2005, 24: 508-512. 10.1097/01.shk.0000190827.36406.6ePubMedCrossRef Pickkers P, Sprong T, Eijk L, Hoeven H, Smits P, Deuren M: Vascular endothelial growth factor is increased during the first 48 hours of human septic shock and correlates with vascular permeability. Shock 2005, 24: 508-512. 10.1097/01.shk.0000190827.36406.6ePubMedCrossRef
15.
go back to reference van der Flier M, van Leeuwen HJ, van Kessel KP, Kimpen JL, Hoepelman AI, Geelen SP: Plasma vascular endothelial growth factor in severe sepsis. Shock 2005, 23: 35-38. 10.1097/01.shk.0000150728.91155.41PubMedCrossRef van der Flier M, van Leeuwen HJ, van Kessel KP, Kimpen JL, Hoepelman AI, Geelen SP: Plasma vascular endothelial growth factor in severe sepsis. Shock 2005, 23: 35-38. 10.1097/01.shk.0000150728.91155.41PubMedCrossRef
16.
go back to reference Yano K, Liaw PC, Mullington JM, Shih SC, Okada H, Bodyak N, Kang PM, Toltl L, Belikoff B, Buras J, Simms BT, Mizgerd JP, Carmeliet P, Karumanchi SA, Aird WC: Vascular endothelial growth factor is an important determinant of sepsis morbidity and mortality. J Exp Med 2006, 203: 1447-1458. 10.1084/jem.20060375PubMedPubMedCentralCrossRef Yano K, Liaw PC, Mullington JM, Shih SC, Okada H, Bodyak N, Kang PM, Toltl L, Belikoff B, Buras J, Simms BT, Mizgerd JP, Carmeliet P, Karumanchi SA, Aird WC: Vascular endothelial growth factor is an important determinant of sepsis morbidity and mortality. J Exp Med 2006, 203: 1447-1458. 10.1084/jem.20060375PubMedPubMedCentralCrossRef
17.
go back to reference Ebihara I, Hirayama K, Kaneko S, Nagai M, Ogawa Y, Fujita S, Usui J, Mase K, Yamagata K, Kobayashi M: Vascular endothelial growth factor and soluble fms-like tyrosine kinase-1 in septic shock patients treated with direct hemoperfusion with a polymyxin B-immobilized fiber column. Ther Apher Dial 2008, 12: 285-291. 10.1111/j.1744-9987.2008.00589.xPubMedCrossRef Ebihara I, Hirayama K, Kaneko S, Nagai M, Ogawa Y, Fujita S, Usui J, Mase K, Yamagata K, Kobayashi M: Vascular endothelial growth factor and soluble fms-like tyrosine kinase-1 in septic shock patients treated with direct hemoperfusion with a polymyxin B-immobilized fiber column. Ther Apher Dial 2008, 12: 285-291. 10.1111/j.1744-9987.2008.00589.xPubMedCrossRef
18.
go back to reference Marshall BC, Xu QP, Rao NV, Brown BR, Hoidal JR: Pulmonary epithelial cell urokinase-type plasminogen activator. Induction by interleukin-1 beta and tumor necrosis factor-alpha. J Biol Chem 1992, 267: 11462-11469.PubMed Marshall BC, Xu QP, Rao NV, Brown BR, Hoidal JR: Pulmonary epithelial cell urokinase-type plasminogen activator. Induction by interleukin-1 beta and tumor necrosis factor-alpha. J Biol Chem 1992, 267: 11462-11469.PubMed
19.
go back to reference Abraham E, Gyetko MR, Kuhn K, Arcaroli J, Strassheim D, Park JS, Shetty S, Idell S: Urokinase-type plasminogen activator potentiates lipopolysaccharide-induced neutrophil activation. J Immunol 2003, 170: 5644-5651.PubMedCrossRef Abraham E, Gyetko MR, Kuhn K, Arcaroli J, Strassheim D, Park JS, Shetty S, Idell S: Urokinase-type plasminogen activator potentiates lipopolysaccharide-induced neutrophil activation. J Immunol 2003, 170: 5644-5651.PubMedCrossRef
20.
go back to reference Reuning U, Sperl S, Kopitz C, Kessler H, Krüger A, Schmitt M, Magdolen V: Urokinase-type plasminogen activator (uPA) and its receptor (uPAR): development of antagonists of uPA/uPAR interaction and their effects in vitro and in vivo . Curr Pharm Des 2003, 9: 1529-1543. 10.2174/1381612033454612PubMedCrossRef Reuning U, Sperl S, Kopitz C, Kessler H, Krüger A, Schmitt M, Magdolen V: Urokinase-type plasminogen activator (uPA) and its receptor (uPAR): development of antagonists of uPA/uPAR interaction and their effects in vitro and in vivo . Curr Pharm Des 2003, 9: 1529-1543. 10.2174/1381612033454612PubMedCrossRef
21.
go back to reference Behzadian MA, Windsor LJ, Ghaly N, Liou G, Tsai NT, Caldwell RB: VEGF-induced paracellular permeability in cultured endothelial cells involves urokinase and its receptor. FASEB J 2003, 17: 752-754.PubMed Behzadian MA, Windsor LJ, Ghaly N, Liou G, Tsai NT, Caldwell RB: VEGF-induced paracellular permeability in cultured endothelial cells involves urokinase and its receptor. FASEB J 2003, 17: 752-754.PubMed
22.
go back to reference Niederman MS, Mandell LA, Anzueto A, Bass JB, Broughton WA, Campbell GD, Dean N, File T, Fine MJ, Gross PA, Martinez F, Marrie TJ, Plouffe JF, Ramirez J, Sarosi GA, Torres A, Wilson R, Yu VL, American Thoracic Society: Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med 2001, 163: 1730-1754.PubMedCrossRef Niederman MS, Mandell LA, Anzueto A, Bass JB, Broughton WA, Campbell GD, Dean N, File T, Fine MJ, Gross PA, Martinez F, Marrie TJ, Plouffe JF, Ramirez J, Sarosi GA, Torres A, Wilson R, Yu VL, American Thoracic Society: Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med 2001, 163: 1730-1754.PubMedCrossRef
23.
go back to reference American Thoracic Society; Infectious Diseases Society of America: Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005, 171: 388-416. 10.1164/rccm.200405-644STCrossRef American Thoracic Society; Infectious Diseases Society of America: Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005, 171: 388-416. 10.1164/rccm.200405-644STCrossRef
24.
go back to reference Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, Fisher CJ Jr, Recombinant human protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group: Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001, 344: 699-709. 10.1056/NEJM200103083441001PubMedCrossRef Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, Fisher CJ Jr, Recombinant human protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group: Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001, 344: 699-709. 10.1056/NEJM200103083441001PubMedCrossRef
25.
go back to reference Karlsson S, Pettilä V, Tenhunen J, Lund V, Hovilehto S, Ruokonen E, Finnsepsis Study Group: Vascular endothelial growth factor in severe sepsis and septic shock. Anesth Analg 2008, 106: 1820-1826. 10.1213/ane.0b013e31816a643fPubMedCrossRef Karlsson S, Pettilä V, Tenhunen J, Lund V, Hovilehto S, Ruokonen E, Finnsepsis Study Group: Vascular endothelial growth factor in severe sepsis and septic shock. Anesth Analg 2008, 106: 1820-1826. 10.1213/ane.0b013e31816a643fPubMedCrossRef
26.
go back to reference Vidal F, Aragonés J, Alfranca A, de Landázuri MO: Up-regulation of vascular endothelial growth factor receptor Flt-1 after endothelial denudation: role of transcription factor Egr-1. Blood 2000, 95: 3387-3395.PubMed Vidal F, Aragonés J, Alfranca A, de Landázuri MO: Up-regulation of vascular endothelial growth factor receptor Flt-1 after endothelial denudation: role of transcription factor Egr-1. Blood 2000, 95: 3387-3395.PubMed
27.
go back to reference Plaschke K, Staub J, Ernst E, Marti HH: VEGF overexpression improves mice cognitive abilities after unilateral common carotid artery occlusion. Exp Neurol 2008, 214: 285-292. 10.1016/j.expneurol.2008.08.014PubMedCrossRef Plaschke K, Staub J, Ernst E, Marti HH: VEGF overexpression improves mice cognitive abilities after unilateral common carotid artery occlusion. Exp Neurol 2008, 214: 285-292. 10.1016/j.expneurol.2008.08.014PubMedCrossRef
28.
go back to reference Shibuya M: Structure and dual function of vascular endothelial growth factor receptor-1 (Flt-1). Int J Biochem Cell Biol 2001, 33: 409-420. 10.1016/S1357-2725(01)00026-7PubMedCrossRef Shibuya M: Structure and dual function of vascular endothelial growth factor receptor-1 (Flt-1). Int J Biochem Cell Biol 2001, 33: 409-420. 10.1016/S1357-2725(01)00026-7PubMedCrossRef
29.
go back to reference Cao D, Mizukami IF, Garni-Wagner BA, Kindzelskii AL, Todd RF, Boxer LA, Petty HR: Human urokinase-type plasminogen activator primes neutrophils for superoxide anion release. Possible roles of complement receptor type 3 and calcium. J Immunol 1995, 154: 1817-1829.PubMed Cao D, Mizukami IF, Garni-Wagner BA, Kindzelskii AL, Todd RF, Boxer LA, Petty HR: Human urokinase-type plasminogen activator primes neutrophils for superoxide anion release. Possible roles of complement receptor type 3 and calcium. J Immunol 1995, 154: 1817-1829.PubMed
30.
go back to reference Prager GW, Breuss JM, Steurer S, Mihaly J, Binder BR: Vascular endothelial growth factor (VEGF) induces rapid prourokinase (pro-uPA) activation on the surface of endothelial cells. Blood 2004, 103: 955-962. 10.1182/blood-2003-07-2214PubMedCrossRef Prager GW, Breuss JM, Steurer S, Mihaly J, Binder BR: Vascular endothelial growth factor (VEGF) induces rapid prourokinase (pro-uPA) activation on the surface of endothelial cells. Blood 2004, 103: 955-962. 10.1182/blood-2003-07-2214PubMedCrossRef
31.
go back to reference Philippé J, Offner F, Declerck PJ, Leroux-Roels G, Vogelaers D, Baele G, Collen D: Fibrinolysis and coagulation in patients with infectious disease and sepsis. Thromb Haemost 1991, 65: 291-295.PubMed Philippé J, Offner F, Declerck PJ, Leroux-Roels G, Vogelaers D, Baele G, Collen D: Fibrinolysis and coagulation in patients with infectious disease and sepsis. Thromb Haemost 1991, 65: 291-295.PubMed
32.
go back to reference Robbie LA, Dummer S, Booth NA, Adey GD, Bennett B: Plasminogen activator inhibitor 2 and urokinase-type plasminogen activator in plasma and leucocytes in patients with severe sepsis. Br J Haematol 2000, 109: 342-348. 10.1046/j.1365-2141.2000.02057.xPubMedCrossRef Robbie LA, Dummer S, Booth NA, Adey GD, Bennett B: Plasminogen activator inhibitor 2 and urokinase-type plasminogen activator in plasma and leucocytes in patients with severe sepsis. Br J Haematol 2000, 109: 342-348. 10.1046/j.1365-2141.2000.02057.xPubMedCrossRef
Metadata
Title
Plasma soluble vascular endothelial growth factor receptor-1 levels predict outcomes of pneumonia-related septic shock patients: a prospective observational study
Authors
Kuang-Yao Yang
Kuan-Ting Liu
Yu-Chun Chen
Chun-Sheng Chen
Yu-Chin Lee
Reury-Perng Perng
Jia-Yih Feng
Publication date
01-02-2011
Publisher
BioMed Central
Published in
Critical Care / Issue 1/2011
Electronic ISSN: 1364-8535
DOI
https://doi.org/10.1186/cc9412

Other articles of this Issue 1/2011

Critical Care 1/2011 Go to the issue